Figure 2From: Integrated safety in tocilizumab clinical trials Rates of serious infections (95% confidence intervals) in the all-exposed population by 6-month periods. PY, patient-years. Multiple occurrences of the same adverse event in a patient in a 6-month period were counted as individual events.Back to article page